DermTech International

170 articles about DermTech International

• DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 01, 2024

  4/1/2024

  DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, announced that effective March 27, 2024, the Compensation Committee of DermTech’s Board of Directors granted an aggregate of 26,240 restricted stock units to eight new employees under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan.

• DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology

  3/8/2024

  DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.

• DermTech Reports Fourth-Quarter 2023 Financial Results

  2/29/2024

  DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, reported its fourth-quarter 2023 financial results.

• DermTech Announces Release Date for Fourth-quarter 2023 Financial Results

  2/13/2024

  DermTech, Inc. will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results.

• DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations

  1/31/2024

  DermTech, Inc. announced additional restructuring actions to prioritize revenue growth, streamline operations and further reduce overall operating expenses.

• DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types

  1/18/2024

  DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from a study evaluating the foundational gene expression assay component of the DermTech Melanoma Test (DMT) across all skin types in the real-world clinical setting.

• DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay

  1/16/2024

  DermTech, Inc. announced that it will discontinue the optional TERT promoter mutation add-on assay for its DermTech Melanoma Test effective March 1, 2024.

• DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)

  1/8/2024

  DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from its Trust 2 Study, which evaluated the foundational gene expression assay component of the DermTech Melanoma Test (DMT) in a real-world clinical setting.

• DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 14, 2023

  12/14/2023

  DermTech, Inc. announced the grant to 15 new employees of restricted stock units representing the contingent right to receive up to an aggregate of 56,230 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan.

• DermTech Reports Third-Quarter 2023 Financial Results

  11/2/2023

  DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, reported its third-quarter 2023 financial results.

• DermTech Announces Release Date for Third-Quarter 2023 Financial Results

  10/12/2023

  DermTech, Inc. will host a conference call and webcast on Thursday, November 2, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's third-quarter 2023 operating and financial results.

• DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)

  9/21/2023

  DermTech, Inc. announced that DermTech’s Compensation Committee has granted an equity award to its new chief commercial officer, Mark Aguillard.

• DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)

  9/19/2023

  DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, announced agreements with Highmark Inc.

• DermTech Appoints Mark Aguillard as Chief Commercial Officer

  9/11/2023

  DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023.

• DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 25, 2023

  8/25/2023

  DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, announced the grant to six new employees of restricted stock units representing the contingent right to receive up to an aggregate of 24,720 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan.

• DermTech Reports Second-Quarter 2023 Financial Results

  8/3/2023

  DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, reported its second-quarter 2023 financial results.

• DermTech Announces Release Date for Second-Quarter 2023 Financial Results

  7/17/2023

  DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, August 3, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's second-quarter 2023 operating and financial results.

• DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

  7/12/2023

  DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, announced a favorable coverage policy from Highmark Inc.

• ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT)

  6/14/2023

  DermTech, Inc. announced that ECRI completed its evaluation of the Pigmented Lesion Assay, the foundational assay for the DermTech Melanoma Test, and changed its rating from ‘Inconclusive’ to ‘Somewhat Favorable’.

• DermTech Announces Contract With Hawaii Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)

  6/7/2023

  DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced an agreement with a Blues plan in Hawaii.